ArticleBMC cancer2025
Evaluating the effects of a resistance exercise intervention for sarcopenia in patients receiving neoadjuvant chemotherapy for breast cancer: study protocol for a randomized controlled trial.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Effects of exercise interventions on sarcopenia-related outcomes in cancer patients and survivors: an umbrella review of systematic reviews and meta-analyses.Journal of cancer survivorship : research and practice · 2026Review
- Exosomal miR-4443 confers cisplatin resistance in breast cancer by inhibiting ferroptosis.Discover oncology · 2026Article
- Sarcopenia in breast cancer: prognostic values and emerging therapeutic strategies.Frontiers in surgery · 2026Review
- Sarcopenia and inflammatory markers in early-stage breast cancer: a retrospective case-control study of NLR, MLR, RDW-CV, and HRR in middle-aged and elderly women.Frontiers in surgery · 2026Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
backgroundSarcopenia is highly prevalent among people being treated for various types of cancers and is associated with adverse clinical impacts including postoperative complications, chemotherapy-related toxicities, and poor survival. These impacts highlight the need for early intervention to mitigate the progression of sarcopenia during treatment. To date, substantial evidence from clinical trials supports the effectiveness of resistance exercise for reducing sarcopenia, yet the specific effects of prehabilitation exercise during neoadjuvant chemotherapy among patients with breast cancer remain underexplored.
methodsThis two-arm randomized controlled trial (RCT) aims to evaluate the effects of a supervised resistance exercise program in addressing sarcopenia, reducing treatment-related adverse effects, alleviating cancer-related symptoms, and improving quality of life (QOL) in patients with breast cancer undergoing neoadjuvant chemotherapy. Forty-six women (aged 20 years or older, diagnosed with breast cancer, and scheduled to start neoadjuvant chemotherapy) will be randomly assigned to either a resistance exercise group or a usual care control group. To overcome potential challenges related to geographic accessibility and treatment side effects, and to improve program completion, the exercise program offers a hybrid model with three expert-supervised exercise sessions per week available both on-site and online. Each supervised session lasts 60 min. Primary and secondary outcome measures include body composition (i.e., muscle mass), muscle strength, physical performance, treatment-related adverse effects, and self-reported cancer-related symptoms and QOL. Assessments will be conducted at baseline (pre-intervention), at 6 and 12 weeks during the intervention, and at completion of the intervention (18 weeks), using validated measures. The study was approved by the institutional review board of Yonsei University Health System's Severance Hospital. DISCUSSION: This proposed pragmatic RCT will provide meaningful insights into the role of resistance exercise in mitigating sarcopenia and its impact on the clinical outcomes of neoadjuvant chemotherapy for breast cancer. The trial is also expected to contribute to the development of evidence-based sarcopenia interventions tailored to patients with breast cancer and to help guide future directions for clinical practice and research.
trial registrationThis trial was prospectively registered in the Clinical Research Information Service (reference number KCT0008961) in the Republic of Korea on November 16, 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.